Selected article for: "death cause and retrospective study"

Title: 2017 ACVIM Forum Research Abstract Program
  • Document date: 2017_6_15
  • ID: ri2w5iby_113
    Snippet: This retrospective, open label, cohort study evaluated IW receiving pimobendan (n = 25; 0.24-0.26 mg/kg PO q12 h); benazepril (n = 24; 0.25-0.5 mg/kg PO q 12 h); methyldigoxin (n = 21; 0.005 mg/kg PO q 12 h); methyldigoxin+benazepril (n = 40); or pimobendan+benazepril (n = 11), for up to 7.8 years. Time to events were estimated by Kaplan Meier method for first onset of CHF, cardiac death, and all-cause mortality using pair-wise comparisons betwee.....
    Document: This retrospective, open label, cohort study evaluated IW receiving pimobendan (n = 25; 0.24-0.26 mg/kg PO q12 h); benazepril (n = 24; 0.25-0.5 mg/kg PO q 12 h); methyldigoxin (n = 21; 0.005 mg/kg PO q 12 h); methyldigoxin+benazepril (n = 40); or pimobendan+benazepril (n = 11), for up to 7.8 years. Time to events were estimated by Kaplan Meier method for first onset of CHF, cardiac death, and all-cause mortality using pair-wise comparisons between groups. Pooled data from 86 IW with echocardiographic follow-up were dichotomized based upon improvement in %FS, LV end-systolic, and LV end-diastolic dimensions into references ranges ('responders'), vs. no echo improvement ('nonresponders'), to compare cardiac survival.

    Search related documents:
    Co phrase search for related documents